)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
BridgeBio Pharma
BridgeBio Pharma (BBIO) investor relations material
BridgeBio Pharma Study result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study result summary12 Feb, 2026
Study background and design
PROPEL-3 was a global, randomized, double-blind, placebo-controlled phase III trial in 113 children aged 3 to <18 years with achondroplasia, evaluating oral infigratinib 0.25 mg/kg/day versus placebo over 52 weeks, the largest age range in any RCT for this condition.
Participants were randomized 2:1 to infigratinib or placebo after at least 6 months in an observational study, with an option for long-term extension.
The primary endpoint was change in annualized height velocity (AHV) at week 52; key secondary endpoints included change in height Z-score and body proportionality.
Efficacy results
Infigratinib achieved a mean difference in AHV of 2.1 cm/year and an LS mean difference of 1.74 cm/year vs. placebo at week 52 (p<0.0001), the largest seen in any RCT for achondroplasia.
The treatment arm reached a mean AHV of 5.96 cm/year, matching average-stature pediatric populations.
Statistically significant improvements were observed in height Z-score (LS mean increase of 0.41 SD, p<0.0001) and body proportionality (LS mean difference -0.05, p<0.05) in children under 8 years.
Efficacy was consistent across all age groups studied.
Safety and tolerability
Infigratinib was well-tolerated, with no serious adverse events, no discontinuations related to the drug, and no safety signals for FGFR1/2 inhibition.
Most adverse events were mild or moderate and balanced between arms; three cases of mild, transient hyperphosphatemia occurred, all resolving without intervention.
Mean serum phosphate levels remained within normal ranges throughout the study.
Significance of body proportionality improvement
Rationale for hypochondroplasia program acceleration
How does oral delivery differentiate infigratinib?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BridgeBio Pharma earnings date
Q4 202520 Feb, 2026
BridgeBio Pharma
Next BridgeBio Pharma earnings date
Q4 202520 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company's lead candidates for the treatment of Fabry disease comprise a pipeline of recombinant enzyme-replacement therapies comprising elaprase and lysosomal-phospholipid-glycoprotein (PLG) analogs. It focuses on developing therapeutics for treating Fabry disease, a rare genetic disorder characterized by progressive loss of kidney function and the buildup of fatty substances that damage blood vessels and organs. BridgeBio Pharma, Inc.i s based in Waltham, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage